anyone watching this stock, page-5

This company has appeared to be flying under the radar of the general investing community recently although not the directors of the company who have been purchasing continually over the last year and a half.

MVP has excellent numbers and promising growth prospects, the new CEO John Sharman (since 2010) has done a great job increasing profit margins and revenues and also bringing new products to market.

The European trial seems to be progressing well with all applicants producing effective and safe results, in time this will open up a huge new market for their main product Penthrox.

I bought recently at 59c and wanted to buy more as funds became available although at 73c the price is offering far less value.